Brief: Disc Says Updated Results From Phase 2 Beacon Study Of Bitopertin

Disc Medicine

12/12/2023 01:32

Dec 11 (Reuters) - Disc Medicine Inc  IRON.O :
    * DISC PRESENTS POSITIVE UPDATED RESULTS FROM PHASE 2 BEACON
STUDY
OF BITOPERTIN AND OTHER PROGRAMS AT THE 65TH AMERICAN SOCIETY OF
HEMATOLOGY (ASH) ANNUAL MEETING
    * DISC MEDICINE INC SAYS BITOPERTIN WAS GENERALLY
WELL-TOLERATED
WITH STABLE HEMOGLOBIN AT BOTH DOSE LEVELS

Source text for Eikon:  ID:nGNX9sHkrr 
Further company coverage:  IRON.O 

 ((Reuters.Briefs@thomsonreuters.com;))